Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus

What You Should Know: 

– Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device.

– The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is designed to provide unprecedented accuracy and personalized insulin delivery. Notably, it’s the first insulin delivery system to directly measure the volume of insulin delivered with each micro-dose.

Addressing Barriers to AID System Adoption:

Despite the proven benefits of AID systems and guidelines from the American Diabetes Association recommending their use for all individuals with T1D, only about 60% of those eligible currently utilize them. Concerns about affordability, limited personalization, and trust in these systems contribute to this gap.

Key Features and Benefits

• iiSure Technology: This proprietary technology includes four checkpoints for accurate insulin delivery and alerts users to blockages up to nine times faster than competing AID systems.
• Personalized Dosing: Cleared for individuals aged six and up with T1D, the twiist system offers tailored dosing to meet individual needs.
• Tidepool Loop Algorithm: The system utilizes the community-driven Tidepool Loop algorithm to automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels.
• Direct Insulin Measurement: The system directly measures the volume of insulin delivered with each micro-dose.
• FreeStyle Libre 3 Plus Integration: Seamless compatibility with Abbott’s advanced CGM sensor.
• Affordability and Flexibility: The twiist AID System is designed to be accessible, with a $0 first month and no more than $50 per month thereafter for eligible individuals with commercial insurance. This accessibility also means that patients can try the system without the typical long-term commitment.

“We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology2 as our first CGM partner, marking a significant milestone as we bring our innovative AID system to market,” said Sequel CEO and Co-Founder Alan Lotvin, MD. “This collaboration highlights our commitment to making advanced diabetes management more accessible and flexible for people living with diabetes. Abbott’s FreeStyle Libre technology, known for its user-friendly design and broad accessibility, complements our innovative system.”

*To be eligible for the twiist Savings Program, participants must have commercial insurance and not be enrolled in programs that pay for prescriptions in whole or in part by Medicare, Medicaid or any other federal or state programs. It is only valid in the United States, and not valid for cash-paying participants, in Puerto Rico or other U.S. Territories, or where prohibited by law. The pay no more than $50 offer is applicable to most participants on commercial insurance, based on copay and coinsurance averages across all tiered cost sharing plan designs, but may not be applicable to participants on high-deductible plans who have not yet reached their deductible. Max benefit per month for covered claims is $200.